Coinciding with the announcement by the WHO about a 50% decrease in number of cases of malaria, TV3 also explains IRB’s discovery of compounds that eliminate malaria in mice. ICREA researcher Lluís Ribas de Pouplana further explains that the treated mice developed an immune memory that protects against future infections.
“La Sexta Columna” television programme has broadcasted a report about the initiative taken by families with relatives that suffer from Friedreich’s Ataxia, a rare illness with no cure. Joined in an association called Genefa, these families raised the funds necessary to launch a research project – involving IRB Barcelona - to find a treatment.
The programme featured Juan Carlos Baiges, head of the association, Meritxell Teixidó, partner researcher in the Peptide and Protein Laboratory at IRB Barcelona, and Javier López Nido, researcher at the Severo Ochoa Centre of Molecular Biology in Madrid, with whom Teixidó works in coordination to carry the project forward.
Cadena Ser radio, like other national and international media, has reported on the results obtained by Lluís Ribas’s team on new borrelidin-based compounds to combat the malaria-causing parasite Plasmodium. This study, published in the PNAS journal, was performed in mice, and showed that the compounds were 100% effective. In addition, the mice developed immune memory against future infections, a feature not achieved previously in an anti-malarial drug.
Listen to the news on Cadena Ser (in Spanish, minute 18)
Olga Viza has interviewed Joan Guinovart, director of IRB Barcelona, on the “Vespre a La 2” programme, broadcasted by TVE. During the interview, they talked about the success of the dance video done by IRB scientists and the achievement of one of the main objectives, namely to raise funds. In addition, the video has also allowed IRB to be known as a leading research centre and has shown the different research programmes being conducted. Furthermore, Joan Guinovart emphasized the good working environment in the IRB community.
They also commented on the importance of government support for research, both from an institution and economical standpoint. The director placed special...
Diario Médico, like many other national and international media, has echoed Patrick Aloy and Miquel Duran’s article, published in the latest issue of Nature Communications. They report on a predictive model that allows the chemical compounds fragments to be related to their positive and negative effects for 20% of human diseases. The results of this study are expected to allow the design of safer drugs, the detection of associations between diseases, and the identification of new uses for drugs that are already on the market.
Excelenciencia.org has published an article that includes statements made by Manuel Palacín after the “Transporters and other Molecular Machines” conference, part of Barcelona Biomed Conferences, which is organised by IRB Barcelona with the support of the BBVA Foundation.
Hosted by IRB Barcelona researchers Manuel Palacín and Miquel Coll, this conference addressed the latest technological advances in membrane protein determination. Given that many of these proteins have the capacity to enter cells, the determination of their structures may allow the design of smart drugs for many types of diseases.
Elconfidencial.com has published an article about the initiative conducted by Iproteos, a spin-off founded by Teresa Tarragó and Ernest Giralt, to finance its research on a drug against schizophrenia through equity crowdfunding. Tarragó explains the results of this experience, the phases that will be reached, and her future projects.
On 30th of November, journalist Carles Pascual wrote a reference in his blog about de second edition of the “Vi per Vida”, that took place the day before in Calella. This reference includes a video report that contains Xavier Ayala and Joan J. Guinovart’s opinions, and also the collaboration of the “Vi per Vida” with the IRB Barcelona.
Facebook album IRB Barcelona "Vi per Vida", Calella 29 November
Interview with Teresa Tarragó, co-founder together with Ernest Giralt of the spin-off Iproteos, about the discovery of new drugs for diseases that affect the central nervous system. Tarragó explains the scope for biotech business opportunities is very big. "The projects have great potential but require a lot of funding. During the valorisation, spin-offs need more support, " says Tarragó. The IRB Barcelona researchers states that in Catalonia there are lots of good ideas but that "if we want more technology transfer we will have to make it carry greater weight when evaluating a researcher’s scientific production."
Article on the Barcelona BioMed conference on membrane proteins, organised by IRB Barcelona and the BBVA Foundation. According to statements made by the organisers Manuel Palacín and Miquel Coll, both at IRB Barcelona, research into the structure of these proteins "paves the way to a wide range of possibilities for the development of new drugs for diseases that currently have no cure and to search for alternative treatments in other conditions for which current drugs are not overly efficient or...